Hospitalized acute exacerbation of COPD impairs flow and nitroglycerin-mediated peripheral vascular dilation

COPD. 2011 Apr;8(2):60-5. doi: 10.3109/15412555.2011.558541.

Abstract

Vascular function, as measured by flow mediated dilation (FMD) and nitroglycerin mediated dilation (NMD), is impaired in COPD. Increases in systemic inflammatory mediators during acute exacerbations of COPD (AECOPD) may further impair vascular function and may account for the increased prevalence of cardiovascular disease in COPD patients. Similarly it may account for the increased morbidity and mortality in COPD patients hospitalized with acute exacerbations. We hypothesized that FMD and NMD would be impaired during AECOPD requiring hospitalization and that vascular function would improve upon AECOPD resolution. We used FMD and NMD to evaluate vascular function in 19 patients hospitalized with AECOPD. FMD and NMD were repeated approximately three months later in 8 of these patients. In these eight patients significant improvements were observed in FMD (2.6 ± 1.5% vs 5.1 ± 2.4%, p = 0.04) and NMD (5.0 ± 2.6% vs 13.3 ± 4.5, p = 0.02) after resolution of their exacerbation. We conclude that endothelial and vascular smooth muscle function is markedly impaired during AECOPD requiring hospitalization and improves following resolution. The systemic vascular impairment that occurs during AECOPD may partially explain the observed increased in cardiac morbidity and mortality that occur in this population.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Brachial Artery / physiopathology*
  • Disease Progression
  • Female
  • Forced Expiratory Volume
  • Hospitalization
  • Humans
  • Male
  • Middle Aged
  • Muscle, Smooth, Vascular / physiopathology*
  • Nitroglycerin / therapeutic use
  • Peripheral Vascular Diseases / complications
  • Peripheral Vascular Diseases / physiopathology*
  • Pulmonary Disease, Chronic Obstructive / complications
  • Pulmonary Disease, Chronic Obstructive / drug therapy
  • Pulmonary Disease, Chronic Obstructive / physiopathology*
  • Vasodilation*
  • Vasodilator Agents / therapeutic use

Substances

  • Vasodilator Agents
  • Nitroglycerin